First Time Loading...

Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 27.75 USD
Updated: Mar 29, 2024

Pfizer Inc
Revenue

Last Value
3-Years CAGR
5-Years CAGR
Quarterly
Annual
TTM
|

Pfizer Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
MRK
ZTS
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Revenue
$58.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
1%
Johnson & Johnson
NYSE:JNJ
Revenue
$85.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45B
CAGR 3-Years
2%
CAGR 5-Years
15%
CAGR 10-Years
11%
Merck & Co Inc
NYSE:MRK
Revenue
$60.1B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
3%
Zoetis Inc
NYSE:ZTS
Revenue
$8.5B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Revenue
$34.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
4%

Pfizer Inc
Revenue Breakdown

Breakdown by Geography
Pfizer Inc

Total Revenue: 58.5B USD
100%
United States: 27.1B USD
46.3%
Emerging Markets: 12B USD
20.5%
Developed Europe: 11.7B USD
19.9%
Developed Rest Of World: 7.8B USD
13.3%
Show More
Show Less

Breakdown by Segments
Pfizer Inc

Total Revenue: 58.5B USD
100%
Biopharma: 57.2B USD
97.8%
Comirnaty Direct Sales And Alliance Revenues: 11.2B USD
19.2%
Eliquis Alliance Revenues And Direct Sales: 6.7B USD
11.5%
Prevnar Family: 6.4B USD
11%
Ibrance: 4.8B USD
8.1%
Vyndaqel Family: 3.3B USD
5.7%
All Other Specialty Care: 2.2B USD
3.8%
All Other Primary Care: 1.8B USD
3%
Xeljanz: 1.7B USD
2.9%
Business Innovation Segment: 1.3B USD
2.2%
Paxlovid: 1.3B USD
2.2%
Pfizer Centreone: 1.3B USD
2.2%
Xtandi Alliance Revenues: 1.2B USD
2%
All Other Anti-Infectives: 1.1B USD
1.9%
Inlyta: 1B USD
1.8%
Nurtec Odt/Vydura: 928m USD
1.6%
Abrysvo: 890m USD
1.5%
Enbrel (Outside The United States And Canada): 830m USD
1.4%
Sulperazon: 757m USD
1.3%
Bosulif: 645m USD
1.1%
Ig Portfolio: 584m USD
1%
Genotropin: 539m USD
0.9%
Lorbrena: 539m USD
0.9%
Zavicefta: 511m USD
0.9%
Inflectra: 490m USD
0.8%
All Other Oncology: 433m USD
0.7%
Benefix: 424m USD
0.7%
Zirabev: 424m USD
0.7%
Zithromax: 406m USD
0.7%
Premarin Family: 397m USD
0.7%
Ruxience: 390m USD
0.7%
Xalkori: 374m USD
0.6%
Retacrit: 340m USD
0.6%
Medrol: 339m USD
0.6%
Bmp2: 338m USD
0.6%
Oxbryta: 328m USD
0.6%
Aromasin: 301m USD
0.5%
Fsme-Immun/Ticovac: 268m USD
0.5%
Somavert: 267m USD
0.5%
Fragmin: 238m USD
0.4%
Besponsa: 236m USD
0.4%
Refacto Af/Xyntha: 230m USD
0.4%
Braftovi: 213m USD
0.4%
Cresemba: 195m USD
0.3%
Bavencio Alliance Revenues: 190m USD
0.3%
Vfend: 187m USD
0.3%
Sutent: 180m USD
0.3%
Nimenrix: 179m USD
0.3%
Mektovi: 174m USD
0.3%
Bicillin: 158m USD
0.3%
Cibinqo: 128m USD
0.2%
Trumenba: 126m USD
0.2%
Trazimera: 91m USD
0.2%
Padcev: 52m USD
0.1%
Adcetris: 46m USD
0.1%
Pfizer Ignite: 44m USD
0.1%
Tukysa: 17m USD
0%
Tivdak: 4m USD
0%
Show More
Show Less

See Also

What is Pfizer Inc's Revenue?
Revenue
58.5B USD

Based on the financial report for Dec 31, 2023, Pfizer Inc's Revenue amounts to 58.5B USD.

What is Pfizer Inc's Revenue growth rate?
Revenue CAGR 10Y
1%

Over the last year, the Revenue growth was -42%. The average annual Revenue growth rates for Pfizer Inc have been 12% over the past three years , 7% over the past five years , and 1% over the past ten years .